318 related articles for article (PubMed ID: 8216498)
1. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
[TBL] [Abstract][Full Text] [Related]
3. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation.
Raiteri M; Arnaboldi L; McGeady P; Gelb MH; Verri D; Tagliabue C; Quarato P; Ferraboschi P; Santaniello E; Paoletti R; Fumagalli R; Corsini A
J Pharmacol Exp Ther; 1997 Jun; 281(3):1144-53. PubMed ID: 9190847
[TBL] [Abstract][Full Text] [Related]
5. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro.
Rogler G; Lackner KJ; Schmitz G
Am J Cardiol; 1995 Jul; 76(2):114A-116A. PubMed ID: 7604784
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Flint OP; Masters BA; Gregg RE; Durham SK
Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
[TBL] [Abstract][Full Text] [Related]
7. Direct effects of statins on the vascular wall.
Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
[TBL] [Abstract][Full Text] [Related]
8. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
Yasunari K; Maeda K; Minami M; Yoshikawa J
Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):937-42. PubMed ID: 11397700
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological control of biosynthesis pathway of mevalonate: effect on the proliferation of arterial smooth muscle cells].
Corsini A; Arnaboldi L; Quarato P; Ferri N; Granata A; Fumagalli R; Paoletti R
C R Seances Soc Biol Fil; 1997; 191(2):169-94. PubMed ID: 9255346
[TBL] [Abstract][Full Text] [Related]
10. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages.
Bernini F; Didoni G; Bonfadini G; Bellosta S; Fumagalli R
Atherosclerosis; 1993 Dec; 104(1-2):19-26. PubMed ID: 8141843
[TBL] [Abstract][Full Text] [Related]
11. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.
Soma MR; Donetti E; Parolini C; Mazzini G; Ferrari C; Fumagalli R; Paoletti R
Arterioscler Thromb; 1993 Apr; 13(4):571-8. PubMed ID: 8466892
[TBL] [Abstract][Full Text] [Related]
12. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes.
Corsini A; Arnaboldi L; Raiteri M; Quarato P; Faggiotto A; Paoletti R; Fumagalli R
Pharmacol Res; 1996 Jan; 33(1):55-61. PubMed ID: 8817647
[TBL] [Abstract][Full Text] [Related]
13. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes.
Corsini A; Raiteri M; Soma M; Fumagalli R; Paoletti R
Pharmacol Res; 1991 Feb; 23(2):173-80. PubMed ID: 1905808
[TBL] [Abstract][Full Text] [Related]
15. [The pharmacology of the statins: the evidence of a direct antiatherosclerotic action].
Raiteri M; Arnaboldi L; Quarato P; Paoletti R; Fumagalli R; Corsini A
Ann Ital Med Int; 1995 Oct; 10 Suppl():35S-42S. PubMed ID: 8562263
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic effects of statins in atherosclerosis and diabetes.
Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.
Nègre-Aminou P; van Vliet AK; van Erck M; van Thiel GC; van Leeuwen RE; Cohen LH
Biochim Biophys Acta; 1997 Apr; 1345(3):259-68. PubMed ID: 9150246
[TBL] [Abstract][Full Text] [Related]
18. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
19. Mevalonate is essential for growth of porcine and human vascular smooth muscle cells in vitro.
Rogler G; Lackner KJ; Schmitz G
Basic Res Cardiol; 1995; 90(6):443-50. PubMed ID: 8773189
[TBL] [Abstract][Full Text] [Related]
20. Direct vascular effects of HMG-CoA reductase inhibitors.
Bellosta S; Bernini F; Ferri N; Quarato P; Canavesi M; Arnaboldi L; Fumagalli R; Paoletti R; Corsini A
Atherosclerosis; 1998 Apr; 137 Suppl():S101-9. PubMed ID: 9694549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
